1Pinol-Ripoll G, Larrode Pellicer P, Garces-Redondo M, et al. Characteristics of Guillain-Barre syndrome in the healthy area III of Aragon Country[J]. An Med Intema,2008,25 (3):108 -112.
2Yang Y, Liu S, Qin Z, et al. Alteration of cystatin C levels in cerebrospinal fluid of patients with Guillain-Barre Syndrome by a proteomical approach [ J ]. Mol Biol Rep,2008,29 ( 3 ) :523 - 525.
3Caporale CM, Papola F, Fioroni MA, et al. Susceptibility to Guillain-Barre syndrome is associated to polymorphisms of CD1 genes [ J ]. J Neuroimmunol,2006,177 ( 1 - 2 ) : 112 - 118.
4Nakatani Y, Hotta S, Utsunomiya I, et al. Car2. 1 Voltage-dependent Ca(2 + ) Channel Current is Inhibited by Serum from Select Patients with Guillain-Barre Syndrome [ J ].Neurochem Res,2008, 14(5) :87 -89.
5Yuki N, Kuwabara S. Axonal Guillain-Barre syndrome: carbohydrate mimicry and pathophysiology [ J ]. J Peripher Nerv Syst, 2007,12(4) :238 -249.
6Odaka M. CSF filtration and interferon-beta for Guillain-Barre syndrome[ J ]. Nippon Rinsho,2008,66 (6) : 1200 - 1204,.
7Nishida H, Kuroda T, Wakita K. Combination therapy with methylprednisolone and high-dose immunoglobulin [ J ]. Nippon Rinsho, 2008,66(6) :1190 - 1194.
9Alshekhlee A, Hussain Z, Sultan B, et al. Guillain-Barre syndrome:incidence and mortality rates in US hospitals[ J ]. Neurology ,2008,70 ( 18 ) : 1608 - 1613.
